18F-Radiolabeled Peptides for Non-Invasive c-Met Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for determining the c-Met status of tumors are invasive, risking morbidity and providing incomplete or outdated information, which can lead to ineffective or harmful anti-Met therapies in cancer treatment.
Innovation Solution
The use of 18F-radiolabeled c-Met binding cyclic peptides for PET imaging allows for non-invasive assessment of c-Met expression in tumors, enabling accurate determination of suitable patients for anti-Met therapy and monitoring treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If biopsy is used to determine c-Met status, then diagnostic information is obtained, but patient morbidity risk increases and sampling completeness decreases
Solution Approach 1:
The patent replaces the mechanical/invasive biopsy procedure with a non-invasive molecular imaging technique. Specifically, it uses radiolabeled peptides that bind to c-Met receptors, allowing visualization and quantification of c-Met expression through PET imaging, thereby eliminating the need for tissue sampling and associated morbidity risks
Solution Approach 2:
The patent introduces radiolabeled peptides as intermediary agents that mediate between the detection system and the target. These peptides specifically bind to c-Met receptors on tumor cells, serving as a bridge that allows external detection of internal molecular status without direct tissue extraction
2Measurement precision
If biopsy is used to determine c-Met status, then diagnostic information is obtained, but tumor burden assessment completeness decreases
Solution Approach 1:
The patent makes the imaging agent universally applicable for multiple assessment functions simultaneously. The same radiolabeled peptide that determines c-Met status also provides information about tumor location, size, and burden, eliminating the need for separate diagnostic procedures and providing comprehensive tumor characterization in a single test
3Loss of time
If archive biopsy samples are used for treatment selection, then treatment decisions can be made, but information currency decreases
Solution Approach 1:
The patent enables preliminary and up-to-date assessment of c-Met status before treatment initiation through non-invasive imaging. This allows clinicians to obtain current tumor characterization data without relying on outdated archive samples, ensuring treatment decisions are based on the most recent tumor status while avoiding time-consuming repeat biopsies
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a safer, more comprehensive evaluation of c-Met status and tumor burden, enabling personalized treatment decisions and early detection of therapy effectiveness, reducing the risk of ineffective or harmful treatments.
Implementation Method 1
The invention employs imaging agents which comprise 18F-radiolabelled c-Met binding cyclic peptides
Implementation Method 2
The use of 18F-radiolabeled c-Met binding cyclic peptides for PET imaging allows for non-invasive assessment of c-Met expression in tumors
Data Source
AI summary
The present invention relates to methods useful in the selection of cancer patients suitable for treatment with therapies directed at c-Met. The method employs imaging agents which comprise 18F-radiolabelled c-Met binding peptides suitable for positron emission tomography (PET) imaging in vivo. Also disclosed are methods of treatment, methods of monitoring therapy directed atc-Met and the use of the imaging agents and peptides in the methods of the invention.